|By Marketwired .||
|November 29, 2013 10:00 AM EST||
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 11/29/13 -- Genome British Columbia is pleased to announce a significant advance in the treatment of Chronic Obstructive Pulmonary Disease (COPD.) This serious lung condition affects 3 million Canadians and costs the Canadian healthcare system nearly $4 billion annually. By applying the power of genomics, this new research project partnership capitalizes on BC-based expertise and novel technology.
Learn how genomics is changing the way we treat COPD.
WHAT An opportunity to interview the researchers and funder behind this innovative project WHEN Interviews available Wednesday, December 4th from 10:00am to 3:00pm and by appointment WHERE Sheraton Wall Centre Hotel Pavilion Ballroom 1088 Burrard St. Vancouver WHO - Mr. Dick Vollett, President & CEO, St. Paul's Hospital Foundation - Dr. Alan Winter, President & CEO, Genome BC - Dr. Don Sin, Project Lead, Professor of Medicine at the University of British Columbia and a respirologist at St. Paul's Hospital - Dr. Jerry Sandbrand, COPD patient
B-Roll video and still photos of Dr. Sin in his laboratory and clinic are available.
About Genome British Columbia:
Genome British Columbia is a catalyst for the life sciences cluster on Canada's West Coast, and manages a cumulative portfolio of over $625M in research projects and science and technology platforms. Working with governments, academia and industry across sectors such as forestry, fisheries, agriculture, environment, bioenergy, mining and human health, the goal of the organization is to generate social and economic benefits for British Columbia and Canada. Genome BC is supported by the Province of British Columbia, the Government of Canada through Genome Canada and Western Economic Diversification Canada and more than 300 international public and private co-funding partners. www.genomebc.ca